Science and Technology : Vaccination Nation, A Race of High Stocks-Stakes

Discussion in 'Science and Technology' started by UBNaturally, Oct 26, 2014.

  1. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    This is primarily related to vaccines, trial, R&D, fast tracking, test subject, challenges, and other content associated with pharmaceutical experiments and development of viral and anti-viral agents.


    When I was younger, I recall my grandmother making claim that "I never had a flu, until I got a flu-shot".

    This comment stuck in my mind as time went on, but as my mind matured the research into her comment lead me deeper into questions that many conscious people have about knowns, unknowns, and known-unknowns.

    There are a few more recognizable issues that have more weight than others when it comes to testing vaccines on live healthy human subjects.

    upload_2014-10-26_11-32-4.png


    This site goes on to make this statement:

    The only reason for not being vaccinated is a serious allergic reaction (such as an anaphylactic reaction) to the vaccine or to one of its components. However, some vaccines, usually ones that contain live virus, should not be used or should be delayed in people with certain conditions:

    • A weakened immune system due to a disorder, such as AIDS, or to drugs that suppress the immune system (immunosuppressants), including corticosteroids
    • Pregnancy
    • Some progressive nervous system disorders, such as Guillain-Barré syndrome


    Complete List of Vaccines Licensed for Immunization and Distribution in the US

    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm


    Influenza Vaccination of Pregnant Women and Protection of Their Infants


    Background
    There are limited data on the efficacy of vaccination against confirmed influenza in pregnant women with and those without human immunodeficiency virus (HIV) infection and protection of their infants.


    Methods
    We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influenza vaccine (IIV3) in South Africa during 2011 in pregnant women infected with HIV and during 2011 and 2012 in pregnant women who were not infected. The immunogenicity, safety, and efficacy of IIV3 in pregnant women and their infants were evaluated until 24 weeks after birth. Immune responses were measured with a hemagglutination inhibition (HAI) assay, and influenza was diagnosed by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays of respiratory samples.


    Results
    The study cohorts included 2116 pregnant women who were not infected with HIV and 194 pregnant women who were infected with HIV. At 1 month after vaccination, seroconversion rates and the proportion of participants with HAI titers of 1:40 or more were higher among IIV3 recipients than among placebo recipients in both cohorts. Newborns of IIV3 recipients also had higher HAI titers than newborns of placebo recipients. The attack rate for RT-PCR–confirmed influenza among both HIV-uninfected placebo recipients and their infants was 3.6%. The attack rates among HIV-uninfected IIV3 recipients and their infants were 1.8% and 1.9%, respectively, and the respective vaccine-efficacy rates were 50.4% (95% confidence interval [CI], 14.5 to 71.2) and 48.8% (95% CI, 11.6 to 70.4). Among HIV-infected women, the attack rate for placebo recipients was 17.0% and the rate for IIV3 recipients was 7.0%; the vaccine-efficacy rate for these IIV3 recipients was 57.7% (95% CI, 0.2 to 82.1).


    Conclusions
    Influenza vaccine was immunogenic in HIV-uninfected and HIV-infected pregnant women and provided partial protection against confirmed influenza in both groups of women and in infants who were not exposed to HIV. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov numbers, NCT01306669 and NCT01306682.)


    upload_2014-10-26_11-0-20.png

    upload_2014-10-26_11-5-53.png


    The difference here is that the flu-virus is purportedly inactive and not live, therefore pregnant women can be used for the trial, and their babies monitored and studied for a period of up to 2 years or more after birth for any adverse effects of the vaccine during pregnancy.

    [​IMG] Eligibility

    Ages Eligible for Study: 18 Years to 39 Years
    Genders Eligible for Study: Female
    Accepts Healthy Volunteers: Yes

    Criteria

    Inclusion Criteria:

    • Pregnant women age > 18 years to < 39 years.
    • Gestational age ≥ 20 weeks to < 34 weeks documented by the approximate date of the last menstrual period and corroborated by physical exam.
    • Documented to be HIV-infected on two assays prior to study-enrollment.
    • Able to understand and comply with planned study procedures.
    • Provides written informed consent prior to initiation of study.

    Estimated Enrollment: 2100
    Study Start Date: March 2011
    Estimated Study Completion Date: May 2014
    Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)


    upload_2014-10-26_11-27-39.png
     
  2. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    First British volunteer injected with trial Ebola vaccine in Oxford

    If vaccine tested on Ruth Atkins and other healthy volunteers is found to work, it will be fast-tracked for use in west Africa

    [​IMG]
    Dr Felicity Hartnell of Oxford University injects Ruth Atkins with the Ebola vaccine.

    A woman in Oxford has become the first British volunteer to be injected with an experimental Ebola vaccine, which, if it works, will be fast-tracked for use in west Africa.

    In an unprecedented move, the untested vaccine has already gone into mass production. Some 10,000 doses are being manufactured by the British drug company GlaxoSmithKline, funded by the Wellcome Trust and the UK government, which are also supporting the Oxford trial.

    If the vaccine is effective, there will be supplies available to protect thousands of health workers in west Africa, who will be the first to receive it. Nobody wants a repeat of the ZMapp experience – only a dozen doses were available worldwide of the experimental drug and, controversially, they went mostly to foreign medical and aid workers.

    The first British volunteer is Ruth Atkins, 48, a communications and engagement manager in the NHS from Marcham in Oxfordshire and a former nurse. She heard on the radio as she was driving home from work that volunteers were needed for a vaccine trial run by Oxford University researchers.

    "I volunteered because the situation in west Africa is so tragic and I thought being part of this vaccination process was something small I could do to hopefully make a huge impact," she said.

    One hour after the vaccination, she said: "I feel absolutely fine, it felt no different to being vaccinated before going on holiday."

    Atkins is the first of 60 healthy people who will be vaccinated to find out whether the potential vaccine has any troublesome side effects. Studies involving animals have shown no ill effects so far.

    The vaccine was under development by GSK – it was in the portfolio of Okairos, a smaller company bought by GSK last year – before the Ebola outbreak occurred, but it could have taken a decade to get it through the trials and into production.

    There is a growing sense of urgency, with the World Bank warning on Wednesday that billions of dollars could be drained from economies in west Africa by the end of next year if the epidemic is not contained. The bank has pledged about $200m in emergency assistance to Guinea, Liberia and Sierra Leone, the three countries worst affected. The US announced on Tuesday it would send 3,000 troops to help tackle the outbreak.

    Four trials of the vaccine will take simultaneously to gather enough safety data and early information on the immune response, which is an indication of whether it will protect against the disease.

    Ten volunteers have already been injected in the US, where the National Institutes of Health has been funding the development of the vaccine against the Ebola Zaire strain and another against Ebola Sudan. If all goes well, there will also be trials in the Gambia and Mali in healthy volunteers.

    It is hoped results from the trials will be available before the end of this year. If the vaccine is effective, it will be given to health workers in Ebola-stricken regions. This will be the only way to find out whether the it really can protect against the disease.

    Prof Adrian Hill, director of the Jenner Institute at the University of Oxford, which is running the trial, said: "Witnessing the events in Africa makes it clear that developing new drugs and vaccines against Ebola should now be an urgent priority. It is tremendous that so many people have worked hard to make this trial happen in a short time, and I am enormously grateful to those volunteers who have come forward to take part and to the funders including the Wellcome Trust, DfID, MRC and MHRA for supporting this trial so quickly.

    "These are initial safety trials of the vaccine and it will be some time before we know whether the vaccine could protect people against Ebola. But we are optimistic that the candidate vaccine may prove useful against the disease in the future."

    Dr Ian Hudson, the Medicines and Healthcare Products Regulatory Agency's chief executive, said the trial proposal was approved with extraordinary speed: "Our priority is to protect public health. Given the importance of Ebola as a risk to public health in some countries in Africa, we fast-tracked the review of the clinical trial application for this vaccine so that it was assessed and authorised by the MHRA's experts in just four working days."


    [​IMG]

    [​IMG]

    [​IMG]

    Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said.
     
  3. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    The economics behind the rush for an Ebola vaccine

    [​IMG]

    Johnson & Johnson is the latest pharmaceutical firm to say it will join the race to find a vaccine for Ebola. The firm has even been talking with rival GlaxoSmithKline about ways to collaborate to speed up development.

    That urgency speaks to the idea that while the epidemic is well under control in the U.S., it’s out of control in West Africa, where the World Health Organization reports nearly 1,000 people have been infected in just the past week.

    “What you are seeing is a collaboration among industry, a collaboration with governments, a collaboration among charities to address what is becoming a horrific public health crisis,” says GSK’s Donna Altenpohl.

    Until recently, developing a vaccine wasn’t viewed as lucrative in the industry. But Adel Mahmoud, former President of Merck Vaccines says the power of this virus is persuasive.

    “What has changed today is failure of almost all control methods that we now exist,” he says.

    Mahmoud says with public health efforts like quarantine and containment falling short it’s now obvious a vaccine is essential. With millions of Africans in need as well as medical workers worldwide, Mahmoud says it’s clear there’s a huge market.

    It’s not clear how profitable that market will be. But believe it or not, that’s a secondary concern right now to drug makers, says USC economist Joel Hay.

    “They hope if they develop good vaccines they can be compensated at some point. But I don’t think they are doing this out of a profit motive, they are doing it because they believe it’s the right thing to do,” he says.

    Certainly down the road, the company that comes up with a vaccine first could score a major public relations win. But right now, Hay says, nobody – including the drug makers – stand to benefit if Ebola spreads beyond West Africa.

    “Just think what would happen if people though that airplanes were not safe to fly in. the economy could be devastated very quickly,” he says.

    Hay says for pharmaceutical companies in the business of making people better it’s gut check time.
     
  4. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    Drugmakers Bet on Ebola Vaccines, Treatments

    Oct 26, 2014
    By MATTHEW PERRONE and DANICA KIRKA Associated Press

    [​IMG]
    In this Wednesday, Oct. 22, 2014 file picture provided by the World Health Organization (WHO), a package of vials in the first shipment of the experimental vaccine known as VSE-EBOV is opened at the Geneva Cantonal hospital in Geneva. The drug has been sent to the U.S. Walter Reed Army Institute of Research in Maryland for testing on healthy volunteers, with preliminary safety results expected by December.

    Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.

    There are no proven drugs or vaccines for Ebola, in large part because the disease is so rare that up until now it's been hard to attract research funding. And the West African nations hardest hit by the outbreak are unlikely to be able to afford new Ebola vaccines and drugs.

    But governments and corporations now are shifting millions of dollars to fight Ebola in the wake of the outbreak that has infected nearly 10,000 people and killed over 4,800. Experts say drugmakers are wagering that international groups and wealthier governments like the U.S. will buy Ebola vaccines and drugs in mass quantities to stockpile them for future use once they're deemed safe.

    "The political bet is that the U.S. and World Health Organization have been so embarrassed and burned by this event that they will be willing to change the way they do business," said Professor Lawrence Gostin of the Georgetown University Law School, who studies global health issues.

    Drugmakers have benefited from stockpiling before. During the bird flu pandemic of 2009, Western governments spent billions to stock up on drugs and vaccines that mostly went unused. Shelf-life varies by product, but can be as little as a year.

    Still, it's unclear who will pay for the Ebola vaccines that are in development, even after a WHO meeting on Thursday that included government officials, drugmakers and philanthropic groups.

    "Something concrete needs to be developed soon," said Dr. Manica Balasegaram of Doctors Without Borders, who attended the meeting. "This needs to done in tandem for us to prepare for when these vaccines are deployed in the larger scale beyond clinical trials."

    Even with the uncertainty, drug companies are rushing to begin testing in patients.

    Johnson & Johnson said last week it will begin safety testing in early January of a vaccine combination that could protect against an Ebola strain that is "highly similar" to the virus that triggered the current outbreak.

    The New Brunswick, New Jersey, company is spending up to $200 million to speed up production of the vaccine, which it licensed in part from a Danish company last month. If safety tests are successful, the company hopes to begin large clinical trials in May 2015.

    The two leading Ebola vaccines in the pipeline have largely been funded by government efforts, but their testing is being completed by a combination of corporate and public financing.

    Human trials of a vaccine co-developed by the U.S. National Institutes of Health and GlaxoSmithKline are being funded by the company, its charitable trust and funds from the U.S. and U.K. governments. It is being tested for safety in the U.S., U.K. and Mali. GSK said it might be able to make about 1 million doses of its vaccine per month by the end of 2015, assuming that some logistical and regulatory hurdles can be overcome.

    A small U.S. drugmaker, NewLink Genetics, holds the license on the second front-runner vaccine, which was initially developed by the Public Health Agency of Canada and has been sent to the U.S. Walter Reed Army Institute of Research in Maryland for testing on healthy volunteers, with preliminary safety results expected by December.
     
  5. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    Has anyone found places where they can volunteer for the vaccination trials?

    Would like to hear the feedback first hand from those that would be interested, as I am sure they pay the test subjects well. Though I believe there is a waiver that must be signed to forgo legal action for punitive damages caused be adverse side affects.

    From what I have heard, the only real solution is a vaccine, meaning everyone will probably become part of the trial of Big Pharma, similar to the measles and the many other semi-imposed vaccines that must be given for population security.

    Bill and Melissa Gates can't have the population getting all screwy now


    Bill sloppily combines this paraphrased sentence which makes it sound more ominous

    Here is his more expounded expressions
    http://www.forbes.com/sites/matthewherper/2011/11/02/the-second-coming-of-bill-gates/

    Basically he goes from birth control and condoms, to thinking vaccination and creating more healthy children will lower the desire for "underdeveloped countries" to have many children.

    To me, it still sounds like what it sounds like, and being a major contributor to International Planned Parenthood as well as a connection to an Oral Vaccination program to eradicate Polio which was claimed by the WHO to cause more cases of Polio and Paralysis in relation to the doses, Bill is trying hard to be Warren Buffet.

    Warren Buffet is an advocate of population control for what it's worth.
    http://www.pop.org/content/warren-buffett-ends-support-for-population-1817


    Billionaires Try to Shrink World’s Population, Report Says

    May 26, 2009
    [​IMG]

    The New York meeting of billionaires Bill Gates, Warren Buffett, David Rockefeller, Eli Broad, George Soros, Ted Turner, Oprah, Michael Bloomberg and others was described by the Chronicle of Philanthropy as an informal gathering aimed at encouraging philanthropy. Just a few billionaires getting together for drinks and dinner and a friendly chat about how to promote charitable giving.

    There was no agenda, we were told. And no plan for a follow-up meeting.

    But in an age of fallen wealth idols, it was inevitable that a meeting of billionaire minds would draw scrutiny. Surely all that money and power in one room had to spell trouble for the rest of us.

    An article in the Times of London, headlined “Billionaire Club in Bid to Curb World Population,” said the issues discussed in the top-secret meeting included health care, education and–by far the most controversial–slowing the global population growth.

    “Taking their cue from Gates they agreed that overpopulation was a priority,” the article said, adding that “this could result in a challenge to some Third World politicians who believe contraception and female education weaken traditional values.”

    These members, along with Gates, have given away more than £45 billion since 1996 to causes ranging from health programs in developing countries to ghetto schools nearer to home.

    They gathered at the home of Sir Paul Nurse, a British Nobel prize biochemist and president of the private Rockefeller University, in Manhattan on May 5
    . The informal afternoon session was so discreet that some of the billionaires’ aides were told they were at “security briefings”.


    Sir Paul Nurse:
    [​IMG]

    Sir Paul Nurse is the President of the Royal Society. He took up the post to start his five year term on 1 December 2010.

    Paul Nurse is a geneticist who works on what controls the division and shape of cells. He was Professor of Microbiology at the University of Oxford, CEO of the Imperial Cancer Research Fund and Cancer Research UK and President of Rockefeller University New York. He is currently Director and Chief Executive of the Francis Crick Institute.

    He was awarded the Nobel Prize for Physiology or Medicine in 2001 and the Royal Society Copley Medal in 2005.



    Where does a Microbiologist from the University of Oxford and Cancer Research fit into these conversations with Warren Buffet, Rockefeller, Soros, Turner, Winfrey, etc?



    Oxford to lead Ebola vaccine trial


    28 Aug 2014

    An unprecedented international consortium, including Oxford, has been assembled to accelerate trials of a candidate Ebola vaccine

    Oxford University’s Jenner Institute is to start clinical safety tests of a candidate Ebola vaccine, aimed at preventing the disease that has killed more than 1,200 people in the current outbreak in West Africa.

    The candidate vaccine will be given to healthy volunteers in the UK, The Gambia and Mali from as early as September, as part of a series of safety trials.

    The human trials of this vaccine, being co-developed by the US National Institutes of Health (NIH) and GlaxoSmithKline (GSK), are to be accelerated with international consortium funding in response to the Ebola epidemic. The World Health Organisation (WHO) has declared the outbreak a public health emergency of international concern.
     
  6. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    So much information in this video that needs to be cross-referenced


    At first glance I was weary of the artificial setup and scripted lines, but the content eventually overcame the shortcomings of the process of delivery.

    Whistleblowers Report Ebola Outbreak as Commercial Crime and Scientific Fraud as International Health Emergency Declared


    Honolulu, HI—A Harvard trained expert in public health and emerging diseases, Dr. Leonard G. Horowitz, claims the 2014 Ebola “outbreak” smacks of scientific fraud and commercial crime.

    In a 24-minute Special Report prepared for public broadcasting on Vimeo’s Revolution Television channel, Dr. Horowitz, an award-winning author and filmmaker, with co-host investigative-journalist Sherri Kane, claims the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) has defrauded people after drug industrialists loosed the Ebola Zaire strain from a bioweapons laboratory refrigerator.

    The only reasonable explanation for the germ’s sudden re-emergence in a different country after years of hiding in a so-called “natural reservoir” is commercial gain and financial crime involving a refrigerator, Horowitz informs viewers.

    To evidence scientific fraud, the whistleblowers use common sense and historic records in reviewing WHO and CDC claims that the “natural reservoir” might be “fruit bats.” That “official story” is “pseudoscience,” according to Horowitz, referencing health officials’ purported finding of four percent (4%) of bats tested in Bangladesh (Asia) were claimed to carry antibodies for “African Ebola.”

    “This is the same pseudoscience and scam the CDC perpetrated in 1967 after Ebola’s mother--the Marburg virus--broke out of three vaccine production plants simultaneously in Germany and Yugoslavia,” the doctor recalled. At that time, American officials claimed antibodies were found in fifty-percent (50%) of monkeys tested, whereas no other lab could duplicate the claim.

    The doctor concludes “major socio-economic and political upheaval” in Liberia, involving officials in both oil and drug industries, best explains the Ebola outbreak that has killed nearly 1,000 people, mostly in Liberia, even though the virus was reported to have first killed people in Guinea.

    “Couple the scientific facts with Dr. Horowitz’s censorship, suffered as a pharmaceutical industry whistleblower, and you have substantial evidence of a corporate conspiracy to commit genocide,” Kane said, angered by Google/YouTube’s cancelation of both journalists’ YouTube channels watched by millions of viewers just as headline news about Ebola was breaking.

    The journalists are requesting activists spread their 24-minute educational video, along with a freely downloadable book chapter on Ebola written by the doctor, to generate public debate on the issue risking people’s lives internationally.

    “Think about it,” Dr. Horowitz said, “the wealthiest, most powerful, untrustworthy people in the world are dictating what can or can’t be discussed or published in the scientific community and in public forums from which decisions and emergency response plans using drugs and vaccines are made. This fact compounds evidence of ‘bad faith,’ ‘foul play,’ and commercial crime.

    Read the full Press Release here:
    us4.campaign-archive2.com/?u=dac6b36582faa47d3a35390fb&id=78677b4a7e

    and here:
    waronwethepeople.com/another-ebola-problem-solved-natural-source-found/
    waronwethepeople.com/ebola-outbreak-2014-smacks-commercial-crime-scientific-fraud/

    Total Mainstream Media Blackout on the truth about the Origins of Ebola:

    waronwethepeople.com/fear-now-cbs-news-censors-ebola-book-authors-name/

    waronwethepeople.com/ubm_protest/

    And these other related articles and videos:

    waronwethepeople.com/medical-conpspiracy-theories-media-behaviors-united-states/



    waronwethepeople.com/spams-expose-cia-google-internet-regulators-pushing-drugs-unfair-competition-dr-leonard-horowitz/



    Even they may be using this as a propaganda attempt, so do just focus on the information and cross-reference it via searches, archives, historical data outlets, libraries, etc.

    We can't believe information just because it is out there, we must take it upon ourselves to look for anomalies and trends that uncover a more accurate representation for the information.


    Stay woke
     
  7. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    Last edited: Nov 10, 2014
  8. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    Malaria cases in Africa
    [​IMG]



    At the end of every seemingly well intended and good hearted speech, their is a sales pitch that concludes with what the product is and why it should be considered.

    Read Bill Gates Senate testimony from 2010

    This is a sample:


    Vaccines

    As many of you may have heard, Melinda and I recently called for this to be the “Decade of Vaccines.” We committed to providing $10 billion over the next ten years in the hopes of saving millions of young lives through vaccines. We made this commitment because we know that vaccines are the single most effective investment we can make. We are making this commitment because it will make a difference, but we can’t do it alone.

    Ten years ago, when the foundation made its first major global health investment of $750 million to launch the Global Alliance for Vaccines and Immunization, now the GAVI Alliance, immunization rates in poor countries were in decline and there was slow progress in introducing vaccines that were readily available in rich nations. Thanks to the work of the GAVI Alliance and other global efforts around polio and measles, global vaccination rates are today at an all time high. Yet 24 million children remain unimmunized, thereby suffering and dying needlessly from diseases we know how to prevent. That’s not acceptable.

    Prior to calling for the Decade of Vaccines, we modeled what would happen if we could further increase access to existing vaccines from today’s 79 percent average to 90 percent. We found that this scale-up could save nearly 8 million lives in the next ten years. While the foundation’s investment is significant, it is not sufficient. Saving these young lives and helping millions more children get a healthy start at life is quite possible, but cannot be achieved by the Gates Foundation alone. It will require a collective effort among donors, developing country governments, and the private sector. Billions of dollars are needed. Even with the foundation’s commitments, and a potential commitment of $90 million by the US government, the GAVI Alliance alone is facing a resource gap approaching $3 billion through 2015. The polio eradication program is facing a gap of more than $1 billion through 2012. We all need to do much more.
    Key to the success in raising global vaccination rates in recent years has been the global partnership model. The Global Polio Eradication Initiative, the Measles Initiative and the GAVI Alliance have demonstrated what is possible when stakeholders bring their respective strengths together under a common cause.

    I am pleased that, as part of GHI, the U.S. has signaled increased support to the GAVI Alliance in addition to its ongoing support of programs including polio and measles. The GAVI Alliance is an innovative public-private partnership that harnesses the unique strengths of global stakeholders (including the World Health Organization, UNICEF, World Bank, donor governments, industry, developing country governments and civil society) to efficiently deliver vaccines to the world’s poorest countries. Since 2000, the GAVI Alliance has reached more than 250 million children and, critically, saved 5 million lives.

    I want to highlight two important features of the GAVI Alliance model as an illustration of why partnerships of this nature are critical in our efforts to improve health in an environment of expanding need and limited resources. First, GAVI has successfully shaped the vaccine market, reducing vaccine prices by guaranteeing developing country markets for the manufacturers. For example, the price of the five-in-one pentavalent vaccine has declined by more than 20 percent since the start of GAVI and 56 of the poorest countries of the world had introduced this vaccine by the end of 2009. Second, the GAVI model emphasizes the practice of cost-sharing. In 2009, 45 of the 49 countries required to co-finance GAVI-supplied vaccines did so. This is a 91 percent success rate.

    The U.S. has been a generous donor in the area of vaccines, contributing $1.8 billion to polio eradication and another $568 million to the GAVI Alliance. We will never have a better chance to eradicate polio than we will in the next three years. The new Global Polio Eradication Initiative 2010-2012 strategy outlines a time-bound, aggressive program, one which takes full advantage of new tools, acknowledges and overcomes previous setbacks, looks to address risks proactively, and builds on the lessons learned in the past several years. We are optimistic that this will strike at the final reservoirs of polio and consign this terrible virus to history. In addition, we now have new vaccines available to help prevent the two leading causes of death among young children – pneumonia and diarrhea – and a mechanism through the GAVI Alliance to make them available to countries in greatest need.

    I recognize that times are tough and it will be an uphill battle to fund the GHI at the level of the President’s request. But, an investment in GAVI will give American taxpayers the best bang for their buck, and the committee should consider increasing the level of funding beyond the administration’s request. Poor countries have an enormous desire to introduce these new vaccines to their children as they recognize their lifesaving potential. The opportunity is immediate. These early investments have positive life-long returns.

    It is our hope that with increasing commitment from the US and the Global Health Initiative, that we are one step closer as a global community to making the Decade of Vaccines, measured by lives saved, a reality.


    Innovation

    Melinda and I have built our foundation on the premise that innovation in product, process, and organization is essential to realize the greatest gains possible for the world’s poor. In the global health arena, we have placed particular attention on science and technological innovation, improving upon existing interventions and driving the development of new ones. Imagine a world with a significantly simplified HIV drug regimen, a malaria drug to which the parasite cannot become resistant, a fever diagnostic test mothers can administer to children in their homes to figure out whether or not the child has pneumonia or malaria, or a revolutionary new manufacturing process that cuts the time and thus the cost of making critical, life saving vaccines in half.

    We can save lives while saving money. Multiple US government agencies – NIH, the Department of Defense, Centers for Disease Control and Prevention, the State Department, the FDA, and USAID - have supported research to advance new global health solutions. The US commitment to innovation – doing things differently, applying the best science and the best minds – is critical as you develop and implement the Global Health Initiative. I would like to underscore the need for investments in clinical trials, including at USAID, to ensure that global health investments are solidly grounded in the scientific evidence of what works best. I would urge you to consider incentives that could increase private sector investments in global health innovation and product development. Experience under current policies such as the Orphan Drug Act (1983) and the Priority Review Voucher provided by the Food and Drug Administration Amendments Act may offer insights into how to design new incentives most efficiently. I pledge the best efforts of my foundation to finding ways in which it can partner with the U.S. government in this work.


    The Potential of U.S. Commitment

    I recognize that you must be able to explain your choices to your constituents and show them what they get for their taxpayer dollars. You must be able to assure them that their money is being spent on efforts that will save lives, reduce suffering, and positively impact our country’s future.


    Complete Senate testimony here:
    http://www.gatesfoundation.org/media-center/speeches/2010/03/2010-senate-testimony

    [​IMG]


    [​IMG]


    More to come, and this next bit makes this all more interesting
     
  9. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    UN, Bill Gates Foundation Push Deadly HPV Shots on Poor Nations Under ‘GAVI Alliance’


    November 18th, 2011

    A new campaign has been launched by an organization known as the GAVI Alliance to vaccinate up to 2 million women and girls with either GlaxoSmithKline’s Cervarix or Merck’s Gardasil by the year 2015. Of course these two HPV shots have been shown to be very dangerous, with Gardasil linked to death, countless adverse reactions, and Cervarix recently outed as similarly threatening.

    Nine countries are candidates for the HPV vaccine campaign, though they are not listed at this time. In addition, the price of the campaign is not being disclosed due to the “sensitive nature” of the price talks.

    Why would an organization supposedly dedicated to enhancing health worldwide push either HPV shot on up to 2 million women and young girls? Considering HPV results in only 1% of cancers, and has a 90% chance to resolve itself within two years, it does not seem worth the dangerous side effects and countless millions that will be spent on the upcoming campaign.

    GAVI Alliance Funded by UN, Vaccine Industry, Monsanto Investor Bill Gates

    The GAVI Alliance, a name relatively unknown to many, is a Geneva-based public-private partnership set up in the year 2000 with financial backing from organizations such as the World Bank, The Bill & Melinda Gates Foundation, the vaccine industry, UNICEF, and many other unidentified philanthropists. It is important to note that a public-private partnership is a government and private industry merger or partnership, meaning that these corporate interests can intertwine with big government.

    Now known as the GAVI Alliance, the public-private partnership was previously known as the Global Alliance for Vaccines and Immunisation. Thanks to a $750 million dollar commitment from the Bill & Melinda Gates Foundation, GAVI launched its initiative to vaccinate millions of individuals worldwide. Of course the Bill & Melinda Gates Foundation also currently holds 500,000 shares of Monsanto, the bloated biotech company responsible for genetically modifying the food supply and creating mutated insect populations through the use of heavily altered biopesticides.

    It was also the Bill & Melinda Gates foundation that funded the release of genetically modified mosquitoes, which were actually released into the environment back in 2010 for testing purposes.

    Bill Gates has personally given an extremely controversial TED talk, in which he states:

    “The world today has 6.8 billion people… that’s headed up to about 9 billion. Now if we do a really great job on new vaccines, health care, reproductive health services, we could lower that by perhaps 10 or 15 percent.”

    Skeptics argue that Gates could not have been talking about vaccine-induced deaths, though Gates clearly does not stutter or correct himself after making the statement. Watch the video of the TED talk below and decide for yourself:



    Before potentially calling for a reduction in world population through vaccination and healthcare, Gates speaks on the phony the issue of CO2 emissions and its effects on climate change. He presents a formula for tracking CO2 emissions as follows: CO2 = P x S x E x C.
    P = People
    S = Services per person
    E = Energy per service
    C = CO2 per energy unit

    Gates then states that “probably one of these numbers is going to have to get pretty close to zero.” The audience laughs as Gates jokingly alludes to the human population being reduced to near zero.

    Even more concerning is the link between GAVI and the vaccine industry. In the past Merck has used bribery and other forms of corruption to push Gardasil on patients through government legislation and policy. In fact, it was revealed that Merck paid key legislators to pass the Gardasil bill that would enable the state to administer Gardasil to girls as young as 12 without parental permissions.


    Read more: http://naturalsociety.com/un-bill-g...or-nations-under-gavi-alliance/#ixzz3I1FoBnV8




    CDC Launches Media Campaigns to Increase Vaccine Use

    8/5/2013

    Federal Vaccine Advisory Committee Update
    By Theresa Wrangham, NVIC Executive Director


    NVIC regularly monitors and reports on activities of federal vaccine advisory committee meetings held by the Centers for Disease Control (CDC) and Food and Drug Administration (FDA). These federal committees include the CDC’s National Vaccine Advisory Committee (NVAC), Advisory Commission on Childhood Vaccines (ACCV), Advisory Committee on Immunization Practices (ACIP) and the FDA’s Vaccines & Related Biological Products Advisory Committee (VRBPAC). NVIC representatives have served as consumer members of several of these committees during the past three decades and NVIC provides oral or written public comment on issues related to federal vaccine research, development, regulation and policymaking, frequently advocating for the inclusion of strong vaccine safety and informed consent protections in government vaccine policies. Vaccine advisory committee meetings are open to the public and committee meeting schedule links are posted on NVIC.org and in the NVIC Newsletter.


    CDC Upset About Low HPV Vaccine Uptake

    During NVAC and ACIP committee meetings held in 2013, CDC officials complained about missed opportunities1 and lack luster uptake of the HPV vaccine across the nation.2 In 2008, the NVAC supported HPV vaccine mandates that included doctors being allowed to give adolescents HPV vaccinations without the knowledge or consent of their parents. The current NVAC HPV Working Group continues to support this policy.

    Both the NVAC and ACIP want increased use of the HPV vaccine by children (boys as well as girls) with NVAC’s HPV working group3 being charged with assisting the government in creating strategies to increase uptake of Merck’s Gardasil and GSK’s Cervarix vaccines. Recommendations from the working group included reframing the vaccine from an STD prevention vaccine to an “anti-cancer” vaccine in a new national media campaign.

    The advertising campaign will attempt to brand HPV vaccine as a public health concern in an effort to end parental opposition to this vaccine. In addition, the CDC and medical trade groups will continue to urge pediatricians to offer HPV shots to all pre-adolescents and teenagers at the same time doctors give other government-recommended vaccines to them. They are also heavily promoting alternative settings for giving vaccines, such as schools and pharmacies.

    HPV-associated cervical cancer is estimated to affect between 11,000 and 13,000 women annually in the U.S. with about 4,000 dying from cervical cancer, usually after many years of undetected and untreated chronic HPV infection. HPV is naturally cleared from the body within two years by more than 90 percent of those who become infected. Routine pap screening for women and early interventions to prevent cervical cancer has reduced cervical cancers in the U.S. by over 70 percent since the 1960’s.4

    The CDC’s report to Congress in 2004,5 clearly stated that the majority of HPV infections “cause no clinical problems and go away on their own without treatment”. This same report touted the effectiveness of pap screening in decreasing the incidence and mortality of cervical cancer, while contributing to a 90 percent cervical cancer survival rate. The HPV vaccine three-shot series currently costs a minimum of $390,6 while a pap test can cost as little as $33.

    This most recent repackaging and aggressive advertising of HPV vaccine by federal health officials raises the question: Is this a wise use of tax dollars in a health care system struggling to stay solvent?


    Adults in the Crosshairs To Become Vaccine Compliant

    Federal agency efforts to target adults and persuade them to toe the government vaccine policy line are underway. The take away from discussions by federal officials and committee members is that adults are non-compliant with government vaccine recommendations and fall far behind the aspirational federal Healthy People 20207 goals set for adult vaccine use. NVAC issued its recommendations8 in 2011 on strategies to increase adult vaccination and this topic is receiving more attention during committee meetings with yet another media and marketing/communications effort9 underway to target adults.

    Current NVAC recommendations look to school entry mandates as a possible model to increase adult vaccine use in partnership with medical trade and other non-government organizations (NGO’s). Should these recommendations pick up steam, they could result in employer-based mandates similar to those already being put into place for health care workers in hospitals and other medical facilities. Already, many workers in health care fields are being forced to receive annual flu shots and other government recommended vaccines as a condition of employment in compliance with Healthy People 2020 goals.

    Source:
    http://www.nvic.org/cdc-launches-media-campaigns-to-increase-vaccine.aspx

    Stop 2014 mass HPV Vaccination in South Africa!


    The South African Minister of Health, Dr. Aaron Motsoaledi, has announced that the government will be buying 520 000 doses of the HPV Vaccine to be given to young girls aged 9 and 10. This is due to happen in February 2014.





    As a group of parents, grandparents, teachers, healthcare practitioners and citizens of South Africa, we are deeply concerned:

    • There is a serious lack of scientific evidence that the HPV (Human papillomavirus) Vaccine is safe to give to young girls. After Gardasil (the name of the HPV Vaccine) was licenced and three doses given to 11 – 12 year old girls, there were thousands of reports of sudden collapse with unconsciousness within 24 hours, seizures, muscle pain and weakness, disabling fatigue, Guillain Barre Syndrome, facial and limb paralysis, brain inflammation, rheumatoid arthritis, lupus, blood clots, optic neuritis, strokes, heart and other serious health problems, including death, following the receipt of this vaccine.

    • As of 2012, there have been a total of 26,304 reports of adverse reactions made to the federal Vaccine Adverse Events Reporting System (VAERS) associated with the HPV Vaccines, including 118 deaths. Please note that these figures do not include all countries – the actual figures are much higher.

    • There is no evidence that this vaccine prevents cervical cancer.

    • Gardasil contains aluminum and polysorbate. Aluminum is neurotoxic; both are known to cause cancer in lab animals and alter immune response.


    Motsoaledi: Big pharma's 'satanic' plot is genocide


    [​IMG]
    17 Jan 2014

    Health minister Aaron Motsoaledi is livid about a pharmaceutical company campaign he says will restrict access to crucial drugs.

    [​IMG]

    Health Minister Aaron Motsoaledi has accused a group of multinational pharmaceutical companies active in South Africa of conspiring against the state, the people of South Africa and the populations of developing countries – and of planning what amounts to mass murder.

    "I am not using strong words; I am using appropriate words. This is genocide," Motsoaledi told the Mail & Guardian on Thursday, in response to a plan he described as a conspiracy of "satanic magnitude" – a plan he called on all South Africans to fight "to the last drop of their blood".

    The plan in question is a nine-page document obtained independently this week by both the M&G and the department of health, blandly titled Campaign to Prevent Damage to Innovation from the Proposed Draft National IP Policy in
    South Africa
    .
    But the contents have Motsoaledi spitting fire and nongovernmental organisations (NGOs) deeply concerned, and its disclosure will likely lead to open war between the various parties – a conflict that all sides believe will have inevitable consequences for the long-term health and wealth of a significant fraction of the world's population.

    Read complete article:
    http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide



    Two months later...



    Motsoaledi launches free HPV vaccine for schoolgirls

    12 Mar 2014

    Health Minister Aaron Motsoaledi has launched an HPV vaccine programme for grade four girls in all government schools.

    South Africa became the first African country on Wednesday to provide grade four girls in all government schools with an expensive cervical cancer vaccine at the state's cost. Health Minister Aaron Motsoaledi launched the vaccine programme at Gonyane Primary School in Bloemfontein.

    The vaccine protects against the sexually acquired human papilloma virus (HPV), which causes about 70% of cervical cancers, according to Helen Rees from the Wits Reproductive Health and HIV Institute.

    Cervical cancer is the second most common cancer among South African women, but is the most deadly because it is often detected too late. Of the 6 000 annual cervical cancer cases, more than half of those who contract it die.

    According to the health department's deputy director general Yogan Pillay, the health department gets the vaccine, Cervarix, at about a fifth of the cost from the manufacturing pharmaceutical company, GlaxoSmithKline.

    Source:
    http://mg.co.za/article/2014-03-12-motsoaledi-launches-free-hpv-vaccine-for-school-girls


    Other sources:
    http://rabble.ca/blogs/bloggers/ger...t-ebola-dont-forget-south-africas-aids-crisis



    Not really sure what to make of this, but bringing in "vaccines" the prevent "cancer", that has a potential adverse side effect of "AIDS" like symptoms, into a population that is one of the more... just look

    [​IMG]






    Who are these people and what are they up to?
     
  10. UBNaturally

    UBNaturally Well-Known Member MEMBER

    Country:
    United States
    Joined:
    Jan 15, 2014
    Messages:
    6,497
    Likes Received:
    1,017
    Gender:
    Male
    Ratings:
    +1,736
    This is not for serious thought, but just for random thoughts

    Thomas Eric Duncan
    [​IMG]

    This photo is odd, not because the female's face is blotted out, but because she is smiling for the camera while "TED" is on the phone not caring too much about the photo.

    Why is she so happy about it? (can see her teeth even after the blotting)

    Here is what the captions state:

    • "15 days ago virus victim Thomas Duncan was warmly greeted by a relative at Dallas airport"

    • "Arrival: Ebola victim Thomas Eric Duncan, 42 greets a woman and phones his family after landing at Dallas-Forth Worth International Airport on September 20th"
    Source:
    http://www.dailymail.co.uk/news/art...eria-bringing-deadly-virus-American-soil.html


    Every time I look at this photo, something more interesting pops out.

    upload_2014-11-10_8-24-31.png
    A disco ball?




    Does Dallas Fort Worth Airport really have a disco ball somewhere?

    Thomas Eric Duncan

    T E D

    [​IMG]



    TED's slogan: "Ideas Worth Spreading"


    Still can't get over that disco ball though.

    Does someone near Dallas have any idea where this is inside the airport?
     
Loading...